Munich Reinsurance Co Stock Corp in Munich Sells 237,281 Shares of Merck & Co., Inc. $MRK

Munich Reinsurance Co Stock Corp in Munich reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 24.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 752,637 shares of the company’s stock after selling 237,281 shares during the period. Merck & Co., Inc. accounts for approximately 2.2% of Munich Reinsurance Co Stock Corp in Munich’s holdings, making the stock its 7th largest holding. Munich Reinsurance Co Stock Corp in Munich’s holdings in Merck & Co., Inc. were worth $90,535,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the fourth quarter worth about $25,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC raised its position in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its outperform rating on Merck and set a $142 price target, signaling meaningful upside from current levels. Benzinga report on RBC rating
• Positive Sentiment: Wells Fargo raised its price target on Merck to $150 and kept an overweight rating, adding to the bullish analyst tone around the stock. Benzinga report on Wells Fargo price target
• Positive Sentiment: Merck’s recent KEYTRUDA approvals in breast and bladder cancer broaden the drug’s use in difficult-to-treat cancers and strengthen the company’s oncology franchise ahead of future exclusivity losses. Article on KEYTRUDA approvals
• Positive Sentiment: Merck also reached a new access agreement for its HIV treatment IDVYNSO, improving commercial access and adding another supportive development for the valuation story. Article on HIV access deal
• Neutral Sentiment: Merck is trading above both its 50-day and 200-day moving averages, which technically supports the stock, but the broader picture still includes patent expiry and vaccine-related concerns. Zacks technical analysis
• Neutral Sentiment: A separate research roundup highlighted Merck alongside other large-cap names, but did not introduce a new company-specific catalyst. Top Research Reports article
• Negative Sentiment: Some commentary noted Merck’s recent pullback and continuing investor focus on its post-Keytruda exclusivity outlook, which remains the main long-term risk to the stock. Article on valuation narrative

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on MRK shares. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Wells Fargo & Company upped their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, CICC Research assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $132.11.

Merck & Co., Inc. Trading Down 2.1%

NYSE:MRK opened at $126.10 on Thursday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business’s 50-day simple moving average is $118.27 and its 200-day simple moving average is $116.06. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The stock has a market capitalization of $311.45 billion, a PE ratio of 35.52, a price-to-earnings-growth ratio of 2.75 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period last year, the company posted $2.22 EPS. The business’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 5.19 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.